Chemotherapy for ER Positive Breast Cancer: 143 Real Stories

143 stories match breast cancer, ER positive and chemotherapy. 134 of them mention surgery.

Cancer Stories

LaShae, who was diagnosed with Breast CancerBreast Cancer

HR-Positive Breast Cancer: LaShae's Patient Story

Patient Info: LaShae, Female, Under 40

Biomarkers: ER-positive; MammaPrint high-risk recurrence; 70-gene hereditary cancer panel negative

As of June 2024, LaShae had completed mastectomy and was undergoing TC chemotherapy, with radiation and long-term hormonal therapy planned; no remission or NED status was stated.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Stage 3 breast cancer: pathologic complete response to neoadjuvant chemotherapy

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive, PR-negative, HER2-negative breast cancer with very high Ki-67. MammaPrint high-risk/basal type; hereditary testing negative.

Free of recurrence at last follow-up after neoadjuvant pembrolizumab plus chemotherapy, breast-conserving surgery with RCB-0/pathologic complete response, adjuvant radiation, and adjuvant pembrolizumab.

PubMed Central
OutcomeCancer-Free / NED
Liz, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Liz's Patient Story

Patient Info: Liz O'Riordan, Female, 40s | Stage III

Biomarkers: ER-positive; HER2-negative; PIK3CA mutation reported by patient

As of June 2024, Liz described Stage III ER-positive/HER2-negative mixed ductal and lobular breast cancer followed by 2 locoregional recurrences after mastectomy; no distant metastatic disease was described for her personal story.

YouTube — Dr Liz O'Riordan
OutcomeSetback / Progression
Allison, who was diagnosed with Stage I Breast CancerBreast Cancer

Stage I HR-Positive Breast Cancer: Allison's Survivor Story

Patient Info: Allison Tierney, Female | Stage I

Biomarkers: ER-positive; PR-positive; HER2-positive

As of May 2024, Allison had recently completed her cancer treatment journey and reported successful hair preservation with cold capping during Taxol chemotherapy.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Invasive lobular breast cancer with isolated scalp metastasis: excision and endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Original breast tumor: ER-positive; PR-positive; scalp metastasis: CK7-positive; ER-positive; GCDFP-15 partially positive

Metastatic Site: scalp/skin

As of April 2024, she had no signs of recurrence in the breast or scalp and no distant metastasis after excision of the isolated scalp metastasis while continuing anastrozole.

PubMed Central
OutcomeCancer-Free / NED
Allison, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Allison's Patient Story

Patient Info: Allison Tierney, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; CHEK2 mutation; BRCA1/2 negative

As of March 2024, Allison had completed Taxol and Herceptin treatment, was on tamoxifen planned for 10 years, and had moved to 6-month oncology follow-up. No metastatic disease or recurrence was reported.

YouTube — The Patient Story
OutcomeCare Ongoing
Dorian, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Dorian's Survivor Story

Patient Info: Dorian de Salvo, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of March 2024, Dorian had a complete response to TCHP chemotherapy, clear surgical margins, and no lymph-node involvement after surgery, with radiation completed and additional care still expected for several months.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic hormone receptor-positive breast cancer with paraneoplastic eosinophilic fasciitis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive; PR-positive; eosinophilia during paraneoplastic eosinophilic fasciitis flare

Metastatic Site: pelvis

As of February 2024, paraneoplastic eosinophilic fasciitis had remitted after prednisone plus systemic breast-cancer therapy, and 6-month follow-up showed no further skin recurrence or cancer progression.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Male Invasive Lobular Breast Cancer With a Pathogenic PALB2 Variant

Patient Info: Anonymized, male, 40s

Biomarkers: ER-positive; PR-positive; HER2 not amplified; pathogenic PALB2 variant

He was disease-free at 1-year follow-up after mastectomy, chemotherapy, and radiotherapy.

PubMed Central
OutcomeCancer-Free / NED
Sally, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Sally's Survivor Story

Patient Info: Sally Johnston, 70+

Biomarkers: Estrogen receptor-positive

Sally was in remission by the end of 2014 and remained active about 10 years after treatment.

Dana-Farber
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Metastatic invasive lobular breast carcinoma to pancreas: biliary stent and paclitaxel

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary breast tumor was triple-negative. Pancreatic metastasis was ER-positive/GATA-positive

Metastatic Site: pancreas; coelio-mesenteric lymph nodes

After 21 years of remission, she developed pancreatic and coelio-mesenteric nodal metastases from invasive lobular breast carcinoma; palliative paclitaxel was stopped after 2 courses because her condition deteriorated, and she was lost to follow-up.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

BRCA2-Positive Breast Cancer in a Woman With Down Syndrome

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-negative, germline BRCA2 pathogenic variant

Metastatic Site: lungs, bones

The cancer later progressed with lung and bone metastases and extensive cancer spread through lymphatic vessels in both lungs. She died 59 months after breast surgery.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage I Breast CancerBreast Cancer

Five Years Without Breast Cancer Recurrence Despite a Markedly Elevated CA 15-3

Patient Info: Anonymized, female, 70+ | Stage I

Biomarkers: ER-positive, PR-positive, HER2-positive

Five years after her Stage I breast-cancer diagnosis, breast imaging and systemic evaluation showed no evidence of recurrence. The markedly elevated CA 15-3 was traced to a separate renal tumor and normalized after nephrectomy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast Cancer Recurs After a 19-Year Remission and Responds to Later Chemotherapy

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Initial tumor: PR-positive, ER-negative, HER2-negative. Recurrence: ER-positive, PR-negative

Metastatic Site: bones

The cancer recurred after a 19-year remission and later spread to bone. More than 21 years after the original diagnosis, she had marked tumor shrinkage, was in good general condition, and had 10 months of progression-free survival after utidelone plus capecitabine.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Male Breast Cancer Controlled for Years Through Multiple Lines of Targeted and Endocrine Therapy

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: Initial tumor ER-positive, PR-positive, HER2-positive; later ER-positive, PR-negative, HER2-negative; PIK3CA mutation; germline BRCA1/2 negative

Metastatic Site: bones, pleura, liver

After a 5-year and 6-month disease-free interval, the cancer recurred in bone and later progressed to the pleura and liver. He died in January 2021, more than 13 years after his 2007 breast-cancer diagnosis.

PubMed Central
OutcomeIn Memory
Susan, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Susan's Survivor Story

Patient Info: Susan, Female, 70+

Biomarkers: 2021 breast cancer described as estrogen-positive and progesterone-positive; HER2 not reported. First breast cancer biomarker status not reported.

As of August 2023, Susan was living in survivorship after a first breast cancer treated with lumpectomy, chemotherapy, and radiation and a later separate breast cancer treated with bilateral mastectomy.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Megan, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Megan's Survivor Story

Patient Info: Megan Claire Chase, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2 not reported

As of July 2023, Megan-Claire was in survivorship after Stage II invasive lobular breast cancer, with clear early scans but significant long-term effects, surgical menopause, chronic pain, fatigue, chemo brain, and inability to tolerate recurrence-prevention medications.

The Patient Story
OutcomeSurvivorship / Completed Treatment